World Health Organization Issues Concern Over Severe Scarcity of Obesity Jabs

Less than a tenth of individuals who could benefit from obesity jabs like Wegovy can access them, states the World Health Organization as it issues its initial advice on the drugs.

Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for increased and just access to this class of drugs.

Per forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.

"The new guidance affirms that obesity is a long-term condition that can be managed with holistic and ongoing care," said its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are significant hurdles to widespread availability to the jabs that can help people shift significant weight, says the body.

Skinny Jab Shortage

Even under the current most optimistic case, the manufacturing of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, per the health organization.

The advice calls on countries and companies to widen access, via approaches including patent sharing.

A patent on a key compound – the core component of the drug Wegovy – is due to expire in multiple countries in 2026.

The Way Obesity Drugs Operate

GLP-1 drugs mimick a biological compound to slow digestion, curb appetite and boost the sense of being full so people consume fewer calories.

Patients typically begin shedding pounds in the initial weeks of starting on the once-weekly jabs.

Research suggests users may regain a significant portion after a year of discontinuing the drug, because their normal food cravings return.

Being overweight or obese elevates your risk for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.

Excess weight impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.